Paliperidone-induced leukopenia and neutropenia: a case report.

摘要

Paliperidone (9-hydroxyrisperidone) is the primary active metabolite of risperidone and INVEGA is an extended release formulation of paliperidone used for the acute and maintenance treatment of schizophrenia. The most commonly reported adverse events of INVEGA are insomnia, headache, akathisia and extrapyramidal symptom-related adverse events including involuntary movements, tremors and muscle stiffness (Emsley et al., 2008). Leukopenia is a decrease in the number of white blood cells (leukocytes) and is often due to neutropenia. Neutropenia can be defined as a neutrophil count of < 1.50x10~9/L Although leukopenia and neutropenia are rare while taking antipsychotic medications, they are serious and potentially life-threatening hematological side effects associated with the use of typical and atypical antipsychotic drugs, especially clozapine. To our knowledge, we report the first case in which a patient developed leukopenia and neutropenia during treatment with paliperidone.